Correction

Khan I, Morris S, Hackshaw A, *et al.* Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy. *BMJ Open* 2015;5:e006733. doi: 10.1136/bmjopen-2014-006733

In figure 1, the top square currently reads '370 Randomised'. This should read '670 Randomised' as mentioned earlier in the text.

Open Access This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>

BMJ Open 2017;0:e006733corr1. doi:10.1136/bmjopen-2014-006733corr1

CrossMark